ArticlePhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology2025
Investigations on MRI changes after 5-aminolevulinic acid mediated interstitial photodynamic therapy for malignant gliomas.
Article in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of glioblastoma still faces challenges due to poor prognosis, necessitating alternative therapies such as interstitial photodynamic therapy (iPDT). Using oral 5-ALA administration and stereotactic light application, iPDT aims to cause a selective, phototoxic effect to the tumor cells. To gain a deeper insight into the intracranial tissue reaction and morphological changes associated with iPDT, this study examined retrospectively MRI sequences (T1, T2, DWI, ADC) in 16 patients at three time points: preoperative (within 7 days before iPDT), postoperative (within 1 day after iPDT), and the first post treatment follow-up (after 3 or 6 months). Significant variations in hypointense, necrotic looking areas, contrast enhancement, edema, diffusion restriction, and hemorrhagic blood volume were found. Postoperative MRI on the day after iPDT showed increased edema volume and diffusion restriction. In T2 images after iPDT, a treatment-related circumscribed structure was identified, which we called "iPDT remnant". It showed substantial overlap with the original tumor. At the first follow-up, the iPDT remnant generally reduced in size, with no further diffusion distortion detected. A small overlap between the initial contrast-enhanced tumor volume and the contrast enhancement on the day after iPDT correlated with more prolonged progression-free survival in this cohort, suggesting it as a potential indicator for iPDT treatment response. These results provide insights into the morphological MRI changes resulting from the iPDT and highlight the importance of MRI, conducted at specific times after the iPDT, for assessing and monitoring the iPDT response. In addition, differences from other forms of therapy and conventional interpretations in neuroradiological evaluation need to be considered.
Indexed as
Identifiers
41324890What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.